Prometic Life Scie Stock Price, News & Analysis (OTCMKTS:PFSCF)

$1.22 -0.05 (-3.77 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$1.27
Today's Range$1.20 - $1.24
52-Week Range$0.90 - $1.96
Volume24,098 shs
Average Volume48,246 shs
Market Capitalization$889.91 million
P/E RatioN/A
Dividend YieldN/A
Beta3.57

About Prometic Life Scie (OTCMKTS:PFSCF)

Prometic Life Scie logoProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Small Molecule Therapeutics and Protein Technology. The Small Molecule Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes, and Alström syndrome. The Protein Technology segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma; bioseparation technologies and products, including Mimetic Ligand purification platform for the pharmaceutical and medical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Receive PFSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for PFSCF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PFSCF
CUSIPN/A
Phone45-0781-0115

Debt

Debt-to-Equity Ratio0.37%
Current Ratio2.76%
Quick Ratio1.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.38 million
Price / Sales70.23
Cash FlowN/A
Price / CashN/A
Book Value$0.19 per share
Price / Book6.43

Profitability

Trailing EPS($0.15)
Net Income$-76,120,000.00
Net Margins-309.26%
Return on Equity-78.90%
Return on Assets-45.61%

Miscellaneous

Employees400
Outstanding Shares711,930,000

Prometic Life Scie (OTCMKTS:PFSCF) Frequently Asked Questions

What is Prometic Life Scie's stock symbol?

Prometic Life Scie trades on the OTCMKTS under the ticker symbol "PFSCF."

When will Prometic Life Scie make its next earnings announcement?

Prometic Life Scie is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Prometic Life Scie.

Who are some of Prometic Life Scie's key competitors?

How do I buy Prometic Life Scie stock?

Shares of Prometic Life Scie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prometic Life Scie's stock price today?

One share of Prometic Life Scie stock can currently be purchased for approximately $1.22.

How big of a company is Prometic Life Scie?

Prometic Life Scie has a market capitalization of $889.91 million and generates $12.38 million in revenue each year. The company earns $-76,120,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Prometic Life Scie employs 400 workers across the globe.

How can I contact Prometic Life Scie?

Prometic Life Scie's mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 45-0781-0115 or via email at [email protected]


MarketBeat Community Rating for Prometic Life Scie (PFSCF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Prometic Life Scie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Prometic Life Scie (OTCMKTS:PFSCF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Prometic Life Scie (OTCMKTS:PFSCF) Consensus Price Target History

Price Target History for Prometic Life Scie (OTCMKTS:PFSCF)

Prometic Life Scie (OTCMKTS:PFSCF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/2/2017Cantor FitzgeraldInitiated CoverageOverweightView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Prometic Life Scie (OTCMKTS:PFSCF) Earnings History and Estimates Chart

Earnings by Quarter for Prometic Life Scie (OTCMKTS:PFSCF)

Prometic Life Scie (OTCMKTS PFSCF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018        
11/13/2017Q3 2017($0.01)$19.17 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.03)$2.69 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.05)$6.44 millionViewN/AView Earnings Details
3/30/2017Q4 2016($0.05)$3.08 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.02)$2.87 millionViewN/AView Earnings Details
8/11/2016Q2 2016($0.03)$2.56 millionViewN/AView Earnings Details
5/12/2016Q1 2016($0.02)$3.83 millionViewN/AView Earnings Details
3/30/2016Q4 2015($0.01)$10.54 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.01)$4.33 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.02)$2.36 millionViewN/AView Earnings Details
5/13/2015Q4 2014$0.04$9.29 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Prometic Life Scie (OTCMKTS:PFSCF) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Prometic Life Scie (OTCMKTS:PFSCF)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prometic Life Scie (OTCMKTS PFSCF)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Prometic Life Scie (OTCMKTS PFSCF) News Headlines

Source:
DateHeadline
Prometic Announces Realignment of its Clinical Program Priorities for 2018Prometic Announces Realignment of its Clinical Program Priorities for 2018
finance.yahoo.com - February 21 at 8:16 AM
Prometic Announces Publication of PBI-4050s Novel Antifibrotic Mechanism of Action in American Journal of PathologyPrometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology
finance.yahoo.com - February 16 at 8:14 AM
Prometic finalizes design of pivotal trial supporting lead drug PBI-4050Prometic finalizes design of pivotal trial supporting lead drug PBI-4050
www.msn.com - January 29 at 9:18 AM
Prometics PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) FinalizedPrometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
finance.yahoo.com - January 29 at 9:18 AM
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
finance.yahoo.com - January 25 at 3:41 PM
ETFs with exposure to ProMetic Life Sciences, Inc. : December 26, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 2:41 PM
ProMetic Life Sciences, Inc. :PFSCF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017ProMetic Life Sciences, Inc. :PFSCF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:22 PM
CANADA STOCKS-TSX inches up with fertilizer company gains, railways weighCANADA STOCKS-TSX inches up with fertilizer company gains, railways weigh
www.cnbc.com - December 11 at 10:53 AM
BRIEF-Prometics PBI-4050 Receives Promising Innovative Medicine Designation From UK MHRABRIEF-Prometic's PBI-4050 Receives Promising Innovative Medicine Designation From UK MHRA
www.reuters.com - December 11 at 10:53 AM
Prometics PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary FibrosisPrometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
finance.yahoo.com - December 11 at 10:53 AM
Pivotal Data for Prometics Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for HematologyPivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
finance.yahoo.com - December 6 at 10:26 AM
Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
finance.yahoo.com - December 1 at 5:27 PM
BRIEF-Prometic reports positive interim clinical data from IVIG phase 3 trialBRIEF-Prometic reports positive interim clinical data from IVIG phase 3 trial
www.reuters.com - November 23 at 7:26 AM
Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 TrialPrometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
finance.yahoo.com - November 23 at 7:26 AM
ProMetic Life Sciences Inc. to Host Earnings CallProMetic Life Sciences Inc. to Host Earnings Call
finance.yahoo.com - November 15 at 7:26 AM

SEC Filings

Prometic Life Scie (OTCMKTS:PFSCF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Prometic Life Scie (OTCMKTS PFSCF) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.